. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Pharmacogenet Genomics. 2011 Dec;21(12):851–860. doi: 10.1097/FPC.0b013e32834c3e74

Table 4.

CRS7 Risk Group and Risks of Outcomes

			All patients – Multivariate^§§			Caucasians only - Multivariate^§§

	CRS7 Risk Group	N	OR/HR (95% CI)	p-value	N	OR/HR (95% CI)	p-value
Fibrosis Progression^*	High	226	1.61 (1.00–2.59)	0.05	158	1.60 (0.95–2.70)	0.08
	Int	161	1.28 (0.76–2.15)	0.35	114	1.30 (0.74–2.30)	0.36
	Low	106	-	-	90	-	-
	Trend	493	1.27 (1.01–1.58)	0.04	362	1.26 (0.98–1.62)	0.07
	CRS7^a Continuous	493	1.13 (1.04–1.22)	0.003	362	1.14 (1.04–1.25)	0.004

Cirrhosis^§	High	440	1.39 (0.98–1.99)	0.07	302	1.39 (0.93–2.07)	0.11
	Int	310	1.13 (0.77–1.64)	0.53	211	1.00 (0.66–1.53)	1.00
	Low	188	-	-	164	-	-
	Trend	938	1.19 (1.00–1.41)	0.05	677	1.19 (0.98–1.45)	0.08
	CRS7^a Continuous	938	1.07 (0.99–1.15)	0.07	677	1.08 (0.99–1.17)	0.08

Clinical outcome^‡	High	440	1.36 (0.95–1.95)	0.09	302	1.34 (0.89–2.02)	0.16
	Int	310	1.30 (0.89–1.90)	0.17	211	1.47 (0.97–2.25)	0.07
	Low	188	-	-	164	-	-
	Trend	938	1.14 (0.97–1.35)	0.12	677	1.12 (0.93–1.36)	0.23
	CRS7^a Continuous	938	1.05 (0.98–1.13)	0.15	677	1.05 (0.97–1.14)	0.21

HCC^‡	High	440	1.65 (0.84–3.24)	0.15	302	1.88 (0.88–4.01)	0.10
	Int	309	1.09 (0.52–2.28)	0.83	210	0.89 (0.36–2.17)	0.79
	Low	188	-	-	164	-	-
	Trend	937	1.34 (0.97–1.85)	0.07	676	1.48 (1.00–2.18)	0.05
	CRS7^a Continuous	937	1.09 (0.96–1.25)	0.19	676	1.14 (0.97–1.33)	0.11

Complementary Log-Log Model (HR).

^§

Logistic Regression Model (OR),

^‡

Cox Proportional Hazards Model (HR).

^§§

Fibrosis Progression, cirrhosis and clinical outcome multivariate models were adjusted for race, patient type, clinical site and treatment assignment.

OR/HR for 0.1-unit change in continuous CRS7

Multivariate HCC models were adjusted for race, treatment assignment, patient type, clinical site and cirrhosis at baseline.

All p-values are derived from two-sided tests.